Get Premium to unlock powerful stock data

Great Point Partners Llc Buys BioAtla Inc, Dicerna Pharmaceuticals Inc, Vertex Pharmaceuticals Inc, Sells Insulet Corp, Collegium Pharmaceutical Inc, Mirati Therapeutics Inc

Author's Avatar
insider
Nov 17, 2021
Article's Main Image
Greenwich, CT, based Investment company Great Point Partners Llc (Current Portfolio) buys BioAtla Inc, Dicerna Pharmaceuticals Inc, Vertex Pharmaceuticals Inc, Cytokinetics Inc, UroGen Pharma, sells Insulet Corp, Collegium Pharmaceutical Inc, Mirati Therapeutics Inc, United Therapeutics Corp, Amicus Therapeutics Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Great Point Partners Llc. As of 2021Q3, Great Point Partners Llc owns 36 stocks with a total value of $429 million. These are the details of the buys and sells.

For the details of GREAT POINT PARTNERS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/great+point+partners+llc/current-portfolio/portfolio

These are the top 5 holdings of GREAT POINT PARTNERS LLC
  1. Exelixis Inc (EXEL) - 1,525,000 shares, 7.51% of the total portfolio. Shares added by 9.39%
  2. Arena Pharmaceuticals Inc (ARNA) - 530,670 shares, 7.36% of the total portfolio. Shares added by 4.94%
  3. Kadmon Holdings Inc (KDMN) - 3,375,000 shares, 6.84% of the total portfolio. Shares reduced by 30.12%
  4. BioAtla Inc (BCAB) - 844,002 shares, 5.79% of the total portfolio. New Position
  5. Rocket Pharmaceuticals Inc (RCKT) - 765,000 shares, 5.32% of the total portfolio. Shares reduced by 6.37%
New Purchase: BioAtla Inc (BCAB)

Great Point Partners Llc initiated holding in BioAtla Inc. The purchase prices were between $29.44 and $43.74, with an estimated average price of $39.07. The stock is now traded at around $27.820000. The impact to a portfolio due to this purchase was 5.79%. The holding were 844,002 shares as of 2021-09-30.

New Purchase: Dicerna Pharmaceuticals Inc (DRNA)

Great Point Partners Llc initiated holding in Dicerna Pharmaceuticals Inc. The purchase prices were between $19.68 and $39.99, with an estimated average price of $27.67. The stock is now traded at around $21.300000. The impact to a portfolio due to this purchase was 3.76%. The holding were 799,999 shares as of 2021-09-30.

New Purchase: Vertex Pharmaceuticals Inc (VRTX)

Great Point Partners Llc initiated holding in Vertex Pharmaceuticals Inc. The purchase prices were between $181.39 and $202.99, with an estimated average price of $195.37. The stock is now traded at around $188.330000. The impact to a portfolio due to this purchase was 3.59%. The holding were 85,000 shares as of 2021-09-30.

New Purchase: Cytokinetics Inc (CYTK)

Great Point Partners Llc initiated holding in Cytokinetics Inc. The purchase prices were between $18.54 and $35.74, with an estimated average price of $29.35. The stock is now traded at around $39.240000. The impact to a portfolio due to this purchase was 3.26%. The holding were 391,429 shares as of 2021-09-30.

New Purchase: UroGen Pharma Ltd (URGN)

Great Point Partners Llc initiated holding in UroGen Pharma Ltd. The purchase prices were between $14.31 and $18.39, with an estimated average price of $15.88. The stock is now traded at around $13.640000. The impact to a portfolio due to this purchase was 2.94%. The holding were 750,000 shares as of 2021-09-30.

New Purchase: Xenon Pharmaceuticals Inc (XENE)

Great Point Partners Llc initiated holding in Xenon Pharmaceuticals Inc. The purchase prices were between $14.86 and $19.45, with an estimated average price of $17.41. The stock is now traded at around $31.990000. The impact to a portfolio due to this purchase was 2.49%. The holding were 700,000 shares as of 2021-09-30.

Added: Biogen Inc (BIIB)

Great Point Partners Llc added to a holding in Biogen Inc by 46.15%. The purchase prices were between $282.99 and $369.05, with an estimated average price of $328.16. The stock is now traded at around $261.550000. The impact to a portfolio due to this purchase was 0.99%. The holding were 47,500 shares as of 2021-09-30.

Added: AnaptysBio Inc (ANAB)

Great Point Partners Llc added to a holding in AnaptysBio Inc by 37.37%. The purchase prices were between $22.98 and $28.1, with an estimated average price of $25.41. The stock is now traded at around $31.780000. The impact to a portfolio due to this purchase was 0.94%. The holding were 549,545 shares as of 2021-09-30.

Added: CytomX Therapeutics Inc (CTMX)

Great Point Partners Llc added to a holding in CytomX Therapeutics Inc by 50.00%. The purchase prices were between $4.32 and $6.43, with an estimated average price of $5.36. The stock is now traded at around $7.390000. The impact to a portfolio due to this purchase was 0.59%. The holding were 1,500,000 shares as of 2021-09-30.

Added: Rigel Pharmaceuticals Inc (RIGL)

Great Point Partners Llc added to a holding in Rigel Pharmaceuticals Inc by 32.00%. The purchase prices were between $3.5 and $4.5, with an estimated average price of $3.95. The stock is now traded at around $2.910000. The impact to a portfolio due to this purchase was 0.4%. The holding were 1,980,000 shares as of 2021-09-30.

Sold Out: Insulet Corp (PODD)

Great Point Partners Llc sold out a holding in Insulet Corp. The sale prices were between $260.36 and $307.27, with an estimated average price of $285.43.

Sold Out: Mirati Therapeutics Inc (MRTX)

Great Point Partners Llc sold out a holding in Mirati Therapeutics Inc. The sale prices were between $132.13 and $177.45, with an estimated average price of $161.17.

Sold Out: Ocular Therapeutix Inc (OCUL)

Great Point Partners Llc sold out a holding in Ocular Therapeutix Inc. The sale prices were between $9.7 and $14.34, with an estimated average price of $11.26.

Sold Out: Intersect ENT Inc (XENT)

Great Point Partners Llc sold out a holding in Intersect ENT Inc. The sale prices were between $18.11 and $28.01, with an estimated average price of $24.68.

Sold Out: Kura Oncology Inc (KURA)

Great Point Partners Llc sold out a holding in Kura Oncology Inc. The sale prices were between $15.42 and $21.72, with an estimated average price of $18.88.

Sold Out: Verve Therapeutics Inc (VERV)

Great Point Partners Llc sold out a holding in Verve Therapeutics Inc. The sale prices were between $46 and $73.99, with an estimated average price of $58.89.



Here is the complete portfolio of GREAT POINT PARTNERS LLC. Also check out:

1. GREAT POINT PARTNERS LLC's Undervalued Stocks
2. GREAT POINT PARTNERS LLC's Top Growth Companies, and
3. GREAT POINT PARTNERS LLC's High Yield stocks
4. Stocks that GREAT POINT PARTNERS LLC keeps buying
Rating:
NaN / 5 ( votes)
Author's Avatar
WRITTEN BY

GuruFocus Screeners

Related Articles

Q&A with Gurus